iRhythm Q3 revenue $147.5M (+18% YoY); gross margin 68.8% up 260 bps

iRhythm Holdings, Inc.

2024-Q3 EPS reported -$3.59 revenue$427,514,000

Revenue $147.5M, up 18% YoY; gross profit $101.5M (+23%); gross margin 68.8% vs 66.2%
Record quarterly registration volume; record new account openings in US; UK billable registrations >10,000
FDA 510(k) clearance for Zio AT updates; commercial launch in Austria, Netherlands, Switzerland, Spain; Japan PMDA approval
Technology license agreement with BioIntelliSense for multi-sensor capabilities; recognized $32.1M IPR&D charge
Unrestricted cash $522.0M at Sep 30; cumulative one million patients registered for Zio monitor

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.